A new brain-dedicated Positron Emission Tomography (PET) system to identify β-amyloid biomarker for the early diagnosis of Alzheimer’s disease and other causes of cognitive decline

Información del proyecto

CAREMIBRAIN

Identificador del acuerdo de subvención: 711323

DOI 10.3030/711323

Proyecto cerrado

Fecha de la firma de la CE 23 Mayo 2016

Fecha de inicio 1 Junio 2016

Fecha de finalización 31 Agosto 2021

Financiado con arreglo a

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coste total € 4 393 596,25

Aportación de la UE € 4 393 596,25

Coordinado por

GENERAL EQUIPMENT FOR MEDICAL IMAGING SA
Spain

Objetivo

ONCOVISION is a Spanish SME specialised in design, development, production and commercialisation of organ-dedicated PET systems. Our company submits the present business innovation project with the overall objectives of (1) marketing an innovative brain-dedicated PET system to early diagnosis of Alzheimer’s disease (AD) and other causes of cognitive decline based on the detection of amyloid-β biomarker in the brain using three 18F-labelled tracers recently approved by FDA and EMEA (Florbetapir, Florbetaben, and Flutemetamol) for their clinical use, and (2) validating the clinical performance of this new diagnostic medical device. This new brain-dedicated PET system, targeted to Mental Disorder Units and Nuclear Medicine Units of hospitals in Europe, USA and Japan, is unique in the market and offers several advantages compared to the whole-body PET systems, such as higher resolution, three times higher sensibility, a competitive price (up to three times lower), need of smaller hospital facilities, and lower radiotracer dose to the patient that leads to a lesser cost to the healthcare system. Due to these improved characteristics, the new brain-dedicated PET system will allow an early detection of AD and other causes of cognitive decline and to use this business opportunity to ensure profitability and growth of ONCOVISION.
A Phase 1 project was previously funded and implemented (Call: H2020-SMEINST-1-2014; Cut-off date: 18th June, 2014; Topic: PHC-12-2014/2015 Clinical research for the validation of biomarkers and/or diagnostic medical devices; Proposal number: 651145). The feasibility study prepared in Phase 1 has verified the technological as well as economic viability of the product and its clinical validation. During Phase 2 the validation of clinical performance of the product will be carried out, to enable commercialisation in Phase 3.

Ámbito científico

• medical and health sciences › basic medicine › neurology › epilepsy
• medical and health sciences › health sciences › public health
• medical and health sciences › basic medicine › neurology › dementia › alzheimer
• medical and health sciences › clinical medicine › psychiatry
• medical and health sciences › clinical medicine › radiology › nuclear medicine

Programa(s)

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.2.1.3. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials
• H2020-EU.3.1.3. - Treating and managing disease

Tema(s)

• PHC-12-2015 - Clinical research for the validation of biomarkers and/or diagnostic medical devices

Convocatoria de propuestas

H2020-SMEInst-2014-2015

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-SMEINST-2-2015

Régimen de financiación

SME-2 - SME instrument phase 2

Coordinador

GENERAL EQUIPMENT FOR MEDICAL IMAGING SA

• Aportación neta de la UEn: € 4 393 596,25
• Dirección: CALLE JERONIMO DE MONSORIU, NUM. 92 PLANTA BJ, PUERTA IZQ ; 46022 Valencia ; España
• Pyme Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención. Sí:
  Región
  Este › Comunitat Valenciana › Valencia/València
• Región: Este › Comunitat Valenciana › Valencia/València
• Tipo de actividad: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Coste total: € 4 393 596,25